FibroGen Inc 409 Illinois St, San Francisco, CA 94158, USA
Posted on 12/01/2016 / 134
Listing Types : Bear Trade
Item Type : Biotechnology
Location : USA West

FibroGen Inc NASDAQ: FGEN
Health Care : Biotechnology

FibroGen, Inc. is a research-based biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of novel therapeutics to treat serious unmet medical needs. Its lead product candidate is roxadustat (FG-4592). It is also engaged in developing products, such as FG-6874, FG-3019 and FG-5200. FG-4592 is an oral small molecule inhibitor of hypoxia-inducible factor-prolyl hydroxylases (HIF-PHs), which acts by stimulating the body’s natural pathway of erythropoiesis or red blood cell production. FG-4592 is in Phase III clinical development for the treatment of anemia in chronic kidney disease (CKD). FG-3019 is a monoclonal antibody, which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), pancreatic cancer, Duchenne muscular dystrophy (DMD) and liver fibrosis. FG-6874 is in Phase I clinical trials, and FG-5200 is a corneal implant medical device, which is in preclinical studies.

FGEN is a bear to me but chart may act bullish who’s buying this watch it.

TAGS
Features
Commodities
Forex
Option
Physical Metal
Stock
Reviews
2.3
Total Score 1 REVIEW
(Ratings Rules - One Star Equals No Rating) Strong Buy: Buy : Hold: Unsure : Sell: Strong Sell :
Leave a review
(Ratings Rules - One Star Equals No Rating) Strong Buy: Buy : Hold: Unsure : Sell: Strong Sell :